New tentative approval for Watson Labs drug dienogest; estradiol valerate

Dienogest; estradiol valerate is the generic ingredient in one branded drug marketed by Bayer Hlthcare and is included in one NDA. There are two patents protecting this compound. This ingredient…
The post New tentative approval for Watson Labs dr…


Drug Patent Expirations for the Week of February 18, 2018

SPRITAM (levetiracetam) Aprecia pharms Patent: 9,463,160 Expiration: Feb 20, 2018 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact [email protected] or…
Th…


New patent for La Jolla drug GIAPREZA

Annual Drug Patent Expirations for GIAPREZA Giapreza is a drug marketed by La Jolla Pharm Co and is included in one NDA. It is available from one supplier. There are…
The post New patent for La Jolla drug GIAPREZA appeared first on DrugPatentWatch.


New tentative approval for Watson Labs drug dienogest; estradiol valerate

Dienogest; estradiol valerate is the generic ingredient in one branded drug marketed by Bayer Hlthcare and is included in one NDA. There are two patents protecting this compound. This ingredient…
The post New tentative approval for Watson Labs dr…


Which pharmaceutical drugs have the most drug patents in Singapore?

This chart shows the drugs with the most patents in Singapore. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…
The post Which pharmaceutical drugs have the most drug patents in…


Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending

Originally published by Er J. Wouters, Panos G. Kavanos, Martin McKee in The Milbank Quarterly, 95: 554–601 under a Creative Commons License. Abstract Policy Points: Our study indicates that there are opportunities…
The post Comparing Generic Dru…


Contribution of NIH funding to new drug approvals 2010–2016

This article was originally published by Ekaterina Galkina Cleary, Jennifer M. Beierlein, Navleen Surjit Khanuja, Laura M. McNamee and Fred D. Ledley in PNAS under a Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC…
The po…


Understanding the Barriers to US Biosimilars

Without a strong biosimilars market, costs for biologics in the US continue trending upward.  The world of drug patents for biosimilars in the United States is far more complex than…
The post Understanding the Barriers to US Biosimilars appeared …


New patent expiration for Medicis drug SOLODYN

Annual Drug Patent Expirations for SOLODYN Solodyn is a drug marketed by Medicis and is included in one NDA. It is available from three suppliers. There are nine patents protecting…
The post New patent expiration for Medicis drug SOLODYN appeared…


Do NOT follow this link or you will be banned from the site!
%d bloggers like this: